Press Resease

Plasma Fractionation Market by Product (Albumin, Protease Inhibitors, Coagulation Factor Concentrates, Immunoglobulins, and Others), by Application (Immunology, Hematology, Neurology, Rheumatology, Pulmonology, and Others), and by End-User (Hospitals & Clinics, Clinical Research Laboratories, Medical and Academic Institutes, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 –2025

Published Date: 04-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-1277 Status : Published

Global plasma fractionation market expected to generate around USD 36.8 billion by 2025, at a CAGR of around 7.2% between 2019 and 2025. The increased penetration of the global plasma fractionation market is largely due to the increased use of immunoglobulins and alpha-1-antitrypsin in areas of medicine and the consistent investments in medicine and R&D, which has resulted in cost-effective procedures.

Description

The report covers a forecast and an analysis of the plasma fractionation market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the plasma fractionation market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the plasma fractionation market on a global and regional level.

In order to give the users of this report a comprehensive view of the plasma fractionation market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Plasma Fractionation Market

The report provides company market share analysis to give a broader overview of the key players in the plasma fractionation market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the plasma fractionation market on a global and regional basis.

The study provides a decisive view of the plasma fractionation market by segmenting it based on product, application, end-user, and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players operating in the global plasma fractionation market are Green Cross, Biotest, Octapharma, LFB, Japan Blood Products, China Biologic Products, CSL, Shanghai RAAS Blood, Kedrion, and BPL.

This report segments the global plasma fractionation market into:

Plasma Fractionation Market: By Product

  • Protease Inhibitors
  • Albumin
  • Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Von Willebrand Factor
    • Prothrombin Complex Concentrate
    • Factor XIII
    • Fibrinogen Concentrates
  • Immunoglobulins
    • Intravenous Immunoglobulins
    • Subcutaneous Immunoglobulins
    • Other Immunoglobulins
  • Others

Plasma Fractionation Market: By Application

  • Immunology
  • Hematology
  • Neurology
  • Rheumatology
  • Pulmonology
  • Others

Plasma Fractionation Market: By End-User

  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Medical and Academic Institutes
  • Others

Global Plasma Fractionation Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Plasma Fractionation Market Revenue, 2016-2025 (USD Billion)
    • 2.2. Global Plasma Fractionation Market: Snapshot
  •  
  • Chapter 3. Plasma Fractionation Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Plasma Fractionation Market drivers: Impact analysis
      • 3.2.2. Increasing use of Immunoglobulins and alpha-1-antitrypsin
      • 3.2.3. High plasma proteins demand
      • 3.2.4. Multiple plasma collection centers
    • 3.3. Market Restraints
      • 3.3.1. High Cost of Plasma Fractionation Treatment
    • 3.4. Opportunities
      • 3.4.1. Emerging Markets
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Product
      • 3.6.2. Market attractiveness analysis, by Application
      • 3.6.3. Market attractiveness analysis, by End-User
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Plasma Fractionation Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Plasma Fractionation Market: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Application Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Plasma Fractionation Market - Product Analysis
    • 5.1. Global Plasma Fractionation Market: Product overview
      • 5.1.1. Global Plasma Fractionation Market revenue share, by Product, 2018 and 2025
    • 5.2. Protease Inhibitors
      • 5.2.1. Global Plasma Fractionation Market for Protease Inhibitors, 2016-2025 (USD Billion)
    • 5.3. Albumin
      • 5.3.1. Global Plasma Fractionation Market for Albumin, 2016-2025 (USD Billion)
    • 5.4. Coagulation Factor Concentrates
      • 5.4.1. Global Plasma Fractionation Market for Coagulation Factor Concentrates, 2016-2025 (USD Billion)
    • 5.5. Immunoglobulins
      • 5.5.1. Global Plasma Fractionation Market for Immunoglobulins, 2016-2025 (USD Billion)
    • 5.6. Others
      • 5.6.1. Global Plasma Fractionation Market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Plasma Fractionation Market - Application Analysis
    • 6.1. Global Plasma Fractionation Market: Application overview
      • 6.1.1. Global Plasma Fractionation Market revenue share, by Application, 2018 and 2025
    • 6.2. Immunology
      • 6.2.1. Global Plasma Fractionation Market for Immunology, 2016-2025 (USD Billion)
    • 6.3. Hematology
      • 6.3.1. Global Plasma Fractionation Market for Hematology, 2016-2025 (USD Billion)
    • 6.4. Neurology
      • 6.4.1. Global Plasma Fractionation Market for Neurology, 2016-2025 (USD Billion)
    • 6.5. Rheumatology
      • 6.5.1. Global Plasma Fractionation Market for Rheumatology, 2016-2025 (USD Billion)
    • 6.6. Pulmonology
      • 6.6.1. Global Plasma Fractionation Market for Pulmonology, 2016-2025 (USD Billion)
    • 6.7. Others
      • 6.7.1. Global Plasma Fractionation Market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Plasma Fractionation Market - End-User Analysis
    • 7.1. Global Plasma Fractionation Market: End-User overview
      • 7.1.1. Global Plasma Fractionation Market revenue share, by End-User, 2018 and 2025
    • 7.2. Hospitals & Clinics
      • 7.2.1. Global Plasma Fractionation Market for Hospitals & Clinics, 2016-2025 (USD Billion)
    • 7.3. Clinical Research Laboratories
      • 7.3.1. Global Plasma Fractionation Market for Clinical Research Laboratories, 2016-2025 (USD Billion)
    • 7.4. Medical and Academic Institutes
      • 7.4.1. Global Plasma Fractionation Market for Medical and Academic Institutes, 2016-2025 (USD Billion)
    • 7.5. Others
      • 7.5.1. Global Plasma Fractionation Market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Global Plasma Fractionation Market - Regional Analysis
    • 8.1. Global Plasma Fractionation Market: Regional overview
      • 8.1.1. Global Plasma Fractionation Market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
      • 8.2.2. North America Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
      • 8.2.3. North America Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.2.4.2. The U.S. Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.2.4.3. The U.S. Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.2.5.2. Rest of North America Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.2.5.3. Rest of North America Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
      • 8.3.2. Europe Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
      • 8.3.3. Europe Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.3.4.2. Germany Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.4.3. Germany Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.3.5. UK
        • 8.3.5.1. UK Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.3.5.2. UK Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.5.3. UK Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.3.6.2. France Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.6.3. France Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.3.7.2. Rest of Europe Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.7.3. Rest of Europe Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
      • 8.4.3. Asia Pacific Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.4.4.2. China Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.4.3. China Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.4.5.2. Japan Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.5.3. Japan Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.4.6.2. India Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.6.3. India Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.4.7.2. Rest of Asia Pacific Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.7.3. Rest of Asia Pacific Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
      • 8.5.2. Latin America Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
      • 8.5.3. Latin America Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.5.4.2. Brazil Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.5.4.3. Brazil Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
        • 8.5.5.2. Rest of Latin America Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
        • 8.5.5.3. Rest of Latin America Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Plasma Fractionation Market revenue, by Product, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa Plasma Fractionation Market revenue, by Application, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa Plasma Fractionation Market revenue, by End-User, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. Octapharma
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Therapy portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. CSL
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Therapy portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Green Cross Corporation
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Therapy portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Biotest
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Therapy portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Japan Blood Products
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Therapy portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. China Biologic Products
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Therapy portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Shanghai RAAS Blood Products
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Therapy portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Kedrion
      • 9.8.1.
      • Overview
      • 9.8.2. Financials
      • 9.8.3. Therapy portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments

Methodology

Free Analysis

Plasma processing is a process to obtain pure components that can be further used for injection and transfusion. The Cohn process (also called cold ethanol fractionation) was developed by Edwin J. Cohn during World War II, which was a major breakthrough in the field of blood plasma fractionation. The preparation of plasma-derived products is an important and rising phenomenon in the human plasma biotechnological industry. Some important proteins extensively used in medical treatments are factor VIII, albumin, and Factor IX. Different methods used to extract plasma are based on cold ethanol fractionation of the human plasma, which breaks it down into its components, gel filtration, and chromatographic methods that offer higher purity and fractionation by polyethylene glycol or by salt.

The increased penetration of the global plasma fractionation market is largely due to the increased use of immunoglobulins and alpha-1-antitrypsin in areas of medicine and the consistent investments in medicine and R&D, which has resulted in cost-effective procedures. The global population has a significant proportion of aged people, who suffer from rare diseases that often require high plasma proteins. There are multiple centers to collect plasma that facilitates smooth treatment and also the subsequent development of the plasma fractionation market globally. Additionally, the increasing patient life span due to better healthcare services, increasing health awareness, rising disposable income and reimbursement policies are also contributing to this market. However, the affordability of plasma products may be a major concern for the patients worldwide.

Global Plasma Fractionation Market

The plasma fractionation market is fragmented on the basis of product, application, and end-user. Based on product, the market is segmented into protease inhibitors, albumin, coagulation factor concentrates (factor IX, prothrombin complex concentrate, factor VIII, Von Willebrand factor, factor XIII, and fibrinogen concentrates), and immunoglobulins (subcutaneous immunoglobulin, intravenous immunoglobulin (IVIG), and other immunoglobulins), and others. The application segment is divided into immunology, hematology, neurology, rheumatology, pulmonology, and others. The end-user segment comprises clinical research laboratories, hospitals and clinics, medical and academic institutes, and others.

North America leads the extraction of plasma proteins and treatment of genetic and blood-related disorders, which makes it the global leader of the plasma fractionation market. The Asia Pacific region exhibits the highest potential to grow notably in the global plasma fractionation market in the years ahead. Increased disposable income, rising lifestyle-related disorders, growing healthcare expenditure, and escalating awareness about health disorders are driving the region’s plasma fractionation market. Additionally, the increasing aging population and cancer prevalence are further driving the plasma fractionation market in the Asia Pacific region.

Some key players operating in the global plasma fractionation market are Green Cross, Biotest, Octapharma, LFB, Japan Blood Products, China Biologic Products, CSL, Shanghai RAAS Blood, Kedrion, and BPL.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com